CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Equillium, Inc. (EQ) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Equillium, Inc. (EQ)

Pharmaceutical Preparations · market cap $110M · as of 2026-10-11

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Equillium, Inc. (EQ) is a small-cap pharmaceutical preparations company with a market cap of about $89M at ~$1.41 per share (~63.4M shares). Our data lists EQ101 in Phase 2 for alopecia areata as the lead and only pipeline asset. The company reports $57.2M in cash and 41.8 months of runway. Annual revenue fell from $41M in 2024 to $0 in 2025.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
EQ101Phase 2Alopecia Areata
Price & technical context
3-month
-48.0%
6-month
-40.8%
12-month
+40.2%
52-wk range
$0.84–$3.20
vs 50-day MA
-18.9%
vs 200-day MA
-38.2%
Realized vol
101.2%
Max drawdown
-79.0%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for EQ (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.